TerminatedPhase 2

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Stopped: Sponsor's Decision

United States3 participantsStarted 2019-11-20

Plain-language summary

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At least 18 years of age
✓. Measurable disease as defined by RECIST v1.1
✓. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
✓. Agree to provide tumor tissue and blood samples for biomarker assessment

Exclusion criteria

✕. Treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or any investigational agent within 28 days prior to the first dose of study treatment.
✕. Prior therapy with a chimeric antigen receptor T cell-containing regimen
✕. History of active autoimmune disease(s) including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, type 1 insulin-dependent diabetes mellitus
✕. History of myocarditis regardless of the cause
✕. History of intolerance to prior checkpoint inhibitor therapy defined as the need to discontinue treatment due to an irAE
✕. History of any syndrome or medical condition that required treatment with systemic steroids (≥10 mg daily prednisone equivalents) or immunosuppressive medications.
✕. History of severe allergic or anaphylactic reactions to human mAb therapy or known hypersensitivity to any Probody therapeutic

What they're measuring

Overall Response Rate by RECIST v 1.1

Timeframe: 1 year

Trial details

NCT IDNCT03993379

SponsorCytomX Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-05-21

Results submitted2021-09-02

View on ClinicalTrials.gov More Solid Tumor trials